

in the immune cell, wherein the immune cell expresses at least one receptor that associates with DAP 10; and wherein the activating occurs responsive to the receptor engaging a corresponding target molecule. In embodiments, the receptor is endogenous, exogenous, or over-expressed. In exemplary embodiments, the receptor is NKG2D. In embodiments, the immune cell, or a plurality thereof, are introduced to a subject in need thereof; and the activating occurs in the subject.

[0020] In a further aspect, the invention provides a use of the mammalian cell of the subject invention, or a plurality thereof, in the preparation of a medicament for treating a subject with a condition for which the mammalian cell, or the plurality thereof, reduces at least one symptom or sign of said condition in the subject.

[0021] In a still further aspect, pharmaceutical compositions are provided comprising a pharmaceutically acceptable excipient and a plurality of mammalian cells of the subject invention.

[0021a] In a further aspect, the invention provides the CAD polypeptide as described herein or the mammalian cell, or a plurality thereof, as described herein for use in therapy.

[0022] Other features, objects, and advantages will be apparent from the disclosure that follows.

INCORPORATION BY REFERENCE

[0023] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] FIGS. 1A-1D are schematic depictions of exemplary chimeric DAP 10 adaptor polypeptides of the present disclosure, in conjunction with a receptor with which they associate. In the depicted illustrations, the receptor is NKG2D. FIG. 1A depicts a chimeric DAP10 adaptor polypeptide with K84R and Y86F modifications; FIG. 1B depicts a chimeric DAP 10 adaptor polypeptide with K84R and Y86F modifications, as well as a C-terminal fusion comprising CD3 ζ signaling domain; FIG. 1C depicts a chimeric DAP 10 adaptor polypeptide with K84R and Y86F modifications, as well as a C-terminal fusion comprising a 4-1BB costimulatory domain; and FIG. 1D depicts a chimeric DAP 10 adaptor polypeptide with K84R and Y86F modifications,